Literature DB >> 30471086

Subclinical atherosclerosis in psoriatic disease: relation to endocan, TNF-α, age of onset, and body fat.

Abdelaal M Elkamshoushi1, Salma S Omar1, Amr M El Abd2, Seham Z Hassan3, Eman A Sultan4, Eman Abd Elkawy1.   

Abstract

BACKGROUND: Psoriasis is a common multisystem inflammatory disease with several associated comorbidities. Serological markers to detect associated subclinical atherosclerosis in psoriatic patients are needed. We aimed to study serum endocan levels in psoriasis vulgaris and its relation to severity of psoriasis, systemic inflammation, associated atherosclerosis, obesity, and the possible factors affecting its level in psoriatic patients.
METHODS: This study was conducted on 30 moderate-severe psoriasis vulgaris patients and 30 healthy controls. Body mass index, body fat percent, and PASI assessments were done. Serum endocan and tumor necrosis factor-α levels were measured by ELISA. Carotid artery intima-media thickness measurement by high-resolution ultrasound was performed.
RESULTS: Psoriasis patients showed significantly higher serum tumor necrosis factor-α and endocan levels (P1 = 0.008, P2 = 0.003). Additionally, there was a statistically significant difference between mean carotid artery intima-media thickness of both groups (P = 0.005). Serum endocan levels positively correlated with PASI score (P = 0.002), tumor necrosis factor-α levels (P < 0.001), mean carotid artery intima-media thickness (P = 0.001), and body mass index (P < 0.001) in the patients group. Additionally, the age of onset of disease negatively correlated with serum endocan (P = 0.003).
CONCLUSION: Serum endocan is a promising marker of severity of psoriasis and associated atherosclerosis. Early onset psoriasis is associated with higher serum endocan levels. Body mass index is positively correlated with serum endocan levels. The positive correlation of endocan and tumor necrosis factor-α supports the regulatory effect of the cytokine on endocan production and suggests the role of endocan as an inflammatory marker.
© 2018 The International Society of Dermatology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30471086     DOI: 10.1111/ijd.14290

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  6 in total

Review 1.  Proteoglycans in Obesity-Associated Metabolic Dysfunction and Meta-Inflammation.

Authors:  Ariane R Pessentheiner; G Michelle Ducasa; Philip L S M Gordts
Journal:  Front Immunol       Date:  2020-05-19       Impact factor: 7.561

2.  Serum endocan levels in relation to traditional and non-traditional anthropometric indices in adult population.

Authors:  Aleksandra Klisić; Nebojša Kavarić; Vesna Spasojević-Kalimanovska; Jelena Kotur-Stevuljević; Ana Ninić
Journal:  J Med Biochem       Date:  2021-01-26       Impact factor: 3.402

Review 3.  Endocan: A Key Player of Cardiovascular Disease.

Authors:  Jinzhi Chen; Liping Jiang; Xiao-Hua Yu; Mi Hu; Yang-Kai Zhang; Xin Liu; Pingping He; Xinping Ouyang
Journal:  Front Cardiovasc Med       Date:  2022-01-05

4.  Serum Endocan Levels and Subclinical Atherosclerosis in Behçet's Syndrome.

Authors:  Eman Mostafa Nassef; Hemmat Ahmed Elabd; Basma Mohamed Mohamed Ali El Nagger; Hala Mohamed Elzomor; Hend Gamal Kotb; Seham Sabry; Boshra Ahmed Zaghloul; Asmaa S Hassan; Eman El Sayed Mohamed
Journal:  Int J Gen Med       Date:  2022-08-18

5.  Serum Endocan Levels and Subclinical Atherosclerosis in Patients with Chronic Kidney and End-Stage Renal Diseases.

Authors:  Fatma M El-Senosy; Rasha Elsayed Mohamed Abd El Aziz; Sammar Ahmed Kasim; Lamia Abdulbary Gad; Donia Ahmed Hassan; Seham Sabry; Ismail Mohamed El Mancy; Taiseer Ahmed Shawky; Ibrahim Ghounim Ramadan Mohamed; Rady Elmonier; Essam Kotb; Abeer Mohammed Abdul-Mohymen
Journal:  Int J Clin Pract       Date:  2022-07-13       Impact factor: 3.149

6.  Elevated Serum Endocan Levels in Patients with Rosacea: A New Therapeutic Target?

Authors:  Sevilay Kılıc; Selda I Mermutlu; Hilal Şehitoğlu; Alper Ekinci
Journal:  Indian J Dermatol       Date:  2021 Sep-Oct       Impact factor: 1.494

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.